Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Afuresertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 known ✓ | P31749 | 12/20 | 0.98 |
| ▸ | AKT2 known ✓ | P31751 | 5/20 | 0.98 |
| ▸ | AKT3 known ✓ | Q9Y243 | 5/20 | 0.98 |
| ▸ | PRKCA | P17252 | 3/20 | 0.98 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.98 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.98 |
| ▸ | PRKCB | P05771 | 2/20 | 0.98 |
| ▸ | PRKACA | P17612 | 2/20 | 0.98 |
| ▸ | PRKACB | P22694 | 2/20 | 0.98 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.98 |
| ▸ | PRKD2 | Q9BZL6 | 2/20 | 0.98 |
| ▸ | CIT | O14578 | 1/20 | 0.98 |
| ▸ | SGK1 | O00141 | 1/20 | 0.57 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.57 |
| ▸ | LATS1 | O95835 | 1/20 | 0.57 |
| ▸ | PRKCG | P05129 | 1/20 | 0.57 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.57 |
| ▸ | PRKCH | P24723 | 1/20 | 0.57 |
| ▸ | MARK3 | P27448 | 1/20 | 0.57 |
| ▸ | PRKCI | P41743 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Afuresertib SCHEMBL1364223 | 1.00 | AKT1 (0.98) | AKT1AKT2AKT3PRKCAROCK1 | |
| Afuresertib SCHEMBL23858298 | 1.00 | AKT1 (0.98) | AKT1AKT2AKT3PRKCAROCK1 | |
| Afuresertib SCHEMBL29360487 | 0.99 | AKT1 (1.00) | AKT1AKT2AKT3PRKCAROCK1 | |
| Afuresertib SCHEMBL187686 | 0.99 | AKT1 (1.00) | AKT1AKT2AKT3PRKCAROCK1 | |
| Afuresertib SCHEMBL15020961 | 0.99 | AKT1 (1.00) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL25062435 | 0.92 | AKT1 (0.87) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL1529676 | 0.92 | AKT1 (0.86) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL1529379 | 0.92 | AKT1 (0.86) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL27791709 | 0.92 | AKT1 (0.86) | AKT1AKT2AKT3PRKCAROCK1 | |
| SCHEMBL12143222 | 0.91 | AKT1 (0.84) | AKT1AKT2AKT3PRKCAROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4125840-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF SYNUCLEINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-02-08 | — | — | EP | claimed |
| US-12595243-B2 | Modulators of extracellular signal-regulated kinase | GEN1E LIFESCIENCES INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250353826-A1 | INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | GEN1E LIFESCIENCES INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12404259-B2 | Inhibitors of extracellular signal-regulated kinase | GEN1E LIFESCIENCES INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250243154-A1 | CRYSTALLINE 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE DI-HYDROCHLORIDE DI-HYDRATE | GEN1E LIFESCIENCES INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250177352-A1 | COMBINATION TREATMENT FOR CANCER | LAEKNA LTD (CN) | 2025-06-05 | — | — | US | disclosed |
| US-20250136571-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | GEN1E LIFESCIENCES INC. | 2025-05-01 | — | — | US | disclosed |
| WO-2025085745-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | GEN1E LIFESCIENCES INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250129038-A1 | INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | UNIVERSITY OF MARYLAND, BALTIMORE | 2025-04-24 | — | — | US | disclosed |
| US-12269792-B2 | Crystalline 5-(dimethylamino)-N-(4-(morpholinomethyl) phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate | GENIE LIFESCIENCES INC. (US) | 2025-04-08 | — | — | US | disclosed |
| US-11358986-B2 | IL-2RBETA binding compounds | MEDIKINE, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20220162224-A1 | P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | GEN1E LIFESCIENCES INC. | 2022-05-26 | — | — | US | disclosed |
| WO-2022098890-A2 | IL-2Rβγc BINDING COMPOUNDS AND USES THEREOF | MEDIKINE, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| US-20220135520-A1 | CRYSTALLINE 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE DI-HYDROCHLORIDE DI-HYDRATE | GEN1E LIFESCIENCES INC. | 2022-05-05 | — | — | US | disclosed |
| US-20220119492-A1 | IL-2R-BETA-GAMMA BINDING COMPOUNDS AND USES THEREOF | JEFFREY W. AND CHRISTINA R. BIRD TRUST U/A/D | 2022-04-21 | — | — | US | disclosed |
| US-20220119493-A1 | IL-7R-ALPHA BINDING COMPOUNDS | SAMSARA BIOCAPITAL, L.P. | 2022-04-21 | — | — | US | disclosed |
| US-20220119465-A1 | DUAL IL-2R AND IL-7R BINDING COMPOUNDS | JEFFREY W. AND CHRISTINA R. BIRD TRUST U/A/D | 2022-04-21 | — | — | US | disclosed |
| US-20220119453-A1 | IL-2ALPHA RECEPTOR SUBUNIT BINDING COMPOUNDS | BLUEBIRD VENTURES I, L.P. | 2022-04-21 | — | — | US | disclosed |
| US-11286260-B2 | P38α mitogen-activated protein kinase inhibitors | GEN1E LIFESCIENCES INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11248030-B2 | Dual IL-2R and IL-7R binding compounds | MEDIKINE, INC. (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12269792-B2 | Crystalline 5-(dimethylamino)-N-(4-(morpholinomethyl) phenyl)naphthalene-1-sulfonamide di-hydrochloride di-hydrate | REN, PKD1, DSP | AKT1 4160/4885AKT2 3915/4885AKT3 3893/4885 |
| US-20250353826-A1 | INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | MAP3K20, MAP3K6, MAP3K19 | AKT1 88/4885AKT2 102/4885AKT3 95/4885 |
| US-12404259-B2 | Inhibitors of extracellular signal-regulated kinase | MAP3K20, MAP3K6, MAP3K19 | AKT1 88/4885AKT2 102/4885AKT3 95/4885 |
| US-20220119465-A1 | DUAL IL-2R AND IL-7R BINDING COMPOUNDS | IL2RA, IL2, IL23R | AKT1 2660/4885AKT2 2697/4885AKT3 2698/4885 |
| US-20250136571-A1 | MODULATORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | MAP3K20, MAP3K6, CDC42BPG | AKT1 64/4885AKT2 73/4885AKT3 47/4885 |
| US-20220135520-A1 | CRYSTALLINE 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE DI-HYDROCHLORIDE DI-HYDRATE | REN, PKD1, DSP | AKT1 4160/4885AKT2 3915/4885AKT3 3893/4885 |
| US-11286260-B2 | P38α mitogen-activated protein kinase inhibitors | MAPKAPK2, MAP3K8, MAP3K1 | AKT1 55/4885AKT2 73/4885AKT3 74/4885 |
| US-20250243154-A1 | CRYSTALLINE 5-(DIMETHYLAMINO)-N-(4-(MORPHOLINOMETHYL)PHENYL)NAPHTHALENE-1-SULFONAMIDE DI-HYDROCHLORIDE DI-HYDRATE | REN, PKD1, DSP | AKT1 4160/4885AKT2 3915/4885AKT3 3893/4885 |
| US-20220119492-A1 | IL-2R-BETA-GAMMA BINDING COMPOUNDS AND USES THEREOF | IL2RA, IL2, IL15RA | AKT1 2469/4885AKT2 2358/4885AKT3 2261/4885 |
| US-20220162224-A1 | P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | MAPKAPK2, MAPK1, MAPK8 | AKT1 59/4885AKT2 84/4885AKT3 91/4885 |
| US-20250129038-A1 | INHIBITORS OF EXTRACELLULAR SIGNAL-REGULATED KINASE | MAP3K20, MAP3K6, MAP3K19 | AKT1 88/4885AKT2 102/4885AKT3 95/4885 |
| US-20250177352-A1 | COMBINATION TREATMENT FOR CANCER | CD274, PDCD1LG2, PDCD1 | AKT1 3656/4885AKT2 1981/4885AKT3 1572/4885 |
| US-20220119493-A1 | IL-7R-ALPHA BINDING COMPOUNDS | IL2RA, IL6ST, IL1RN | AKT1 1942/4885AKT2 2839/4885AKT3 2290/4885 |
| US-11248030-B2 | Dual IL-2R and IL-7R binding compounds | IL2RA, IL2, IL23R | AKT1 2660/4885AKT2 2697/4885AKT3 2698/4885 |
| US-12595243-B2 | Modulators of extracellular signal-regulated kinase | CDC42BPG, GRK3, ERBB2 | AKT1 88/4885AKT2 74/4885AKT3 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.